DFN-11
Phase 3Completed 1 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Episodic Migraine
Conditions
Episodic Migraine
Trial Timeline
Sep 21, 2015 → Feb 26, 2018
NCT ID
NCT02569853About DFN-11
DFN-11 is a phase 3 stage product being developed by Dr. Reddy's Laboratories for Episodic Migraine. The current trial status is completed. This product is registered under clinical trial identifier NCT02569853. Target conditions include Episodic Migraine.
What happened to similar drugs?
3 of 15 similar drugs in Episodic Migraine were approved
Approved (3) Terminated (1) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02569853 | Phase 3 | Completed |
| NCT02571049 | Phase 2 | Completed |
Competing Products
19 competing products in Episodic Migraine
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Galcanezumab | Eli Lilly | Phase 3 | 40 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 44 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 40 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 40 |
| BOTOX + Placebo | AbbVie | Phase 3 | 32 |
| Atogepant 60 mg | AbbVie | Phase 3 | 40 |
| Atogepant + Ubrogepant | AbbVie | Approved | 43 |
| Atogepant + Placebo-Matching Atogepant | AbbVie | Phase 3 | 47 |
| SOM230 + Placebo | Novartis | Phase 2 | 27 |
| AMG334 + Oral Prophylactic | Novartis | Approved | 43 |
| AMG334 (70 mg) Pre-Filled Syringe (PFS) + Placebo Pre-Filled Syringe (PFS) | Novartis | Phase 3 | 40 |
| Erenumab | Novartis | Phase 3 | 40 |
| Placebo + AMG 301 | Amgen | Phase 2 | 35 |
| Placebo + MS Contin (morphine sulfate, controlled release) + EMBEDA (morphine sulfate / naltrexone hydrochloride) | Pfizer | Phase 1 | 29 |
| Eptinezumab + Placebo | Lundbeck | Phase 3 | 44 |
| Eptinezumab + Placebo | Lundbeck | Phase 3 | 37 |
| Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A | Ipsen | Phase 3 | 41 |
| IPN10200 + IPN10200 dose A + IPN10200 dose B | Ipsen | Phase 2 | 39 |
| Methylprednisolone | Brain Biotech | Approved | 33 |